CD36 induces hepatosteatosis and may contribute to the development of NASH, and several clinical studies have shown that CD36 is closely associated with NAFLD patients and positively correlated with the degree of steatosis in the liver [59]. Here, CD36 is linked to metabolic dysfunction-associated steatohepatitis.